Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) ...

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, Ratings reports.

Relay Therapeutics (NASDAQ:RLAY – Free Report) had its price objective lowered by The Goldman Sachs Group from $20.00 to ...